{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:10:26Z","timestamp":1793725826095,"version":"4.6.1"},"reference-count":212,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:00:00Z","timestamp":1775088000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"vor","delay-in-days":41,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Stem Cell Res Ther"],"DOI":"10.1186\/s13287-026-04993-8","type":"journal-article","created":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T06:48:34Z","timestamp":1775112514000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Bridging biomaterials and immunotherapy: hydrogel strategies for next-generation CAR-T cell treatment"],"prefix":"10.1186","volume":"17","author":[{"given":"Shayda","family":"Shojaei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahsa","family":"Sani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Negar","family":"Azarpira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona","family":"Latifi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farnaz","family":"Sani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,2]]},"reference":[{"issue":"3","key":"4993_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"7","key":"4993_CR2","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1097\/CM9.0000000000001474","volume":"134","author":"W Cao","year":"2021","unstructured":"Cao W, Chen HD, Yu YW, Li N, Chen WQ. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020. Chin Med J (Engl). 2021;134(7):783\u201391.","journal-title":"Chin Med J (Engl)"},{"issue":"6","key":"4993_CR3","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/S1470-2045(22)00270-4","volume":"23","author":"F Bray","year":"2022","unstructured":"Bray F, Parkin DM. Cancer in Sub-Saharan Africa in 2020: a review of current estimates of the national burden, data gaps, and future needs. Lancet Oncol. 2022;23(6):719\u201328.","journal-title":"Lancet Oncol"},{"issue":"2","key":"4993_CR4","first-page":"171","volume":"104","author":"KP Trayes","year":"2021","unstructured":"Trayes KP, Cokenakes SEH. Breast cancer treatment. Am Fam Physician. 2021;104(2):171\u20138.","journal-title":"Am Fam Physician"},{"issue":"2","key":"4993_CR5","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41571-021-00565-2","volume":"19","author":"G Bianchini","year":"2022","unstructured":"Bianchini G, De Angelis C, Licata L, Gianni L. Treatment landscape of triple-negative breast cancer - expanded options, evolving needs. Nat Rev Clin Oncol. 2022;19(2):91\u2013113.","journal-title":"Nat Rev Clin Oncol"},{"issue":"12","key":"4993_CR6","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.1158\/1535-7163.MCT-20-0385","volume":"19","author":"S Dees","year":"2020","unstructured":"Dees S, Ganesan R, Singh S, Grewal IS. Emerging CAR-T cell therapy for the treatment of triple-negative breast cancer. Mol Cancer Ther. 2020;19(12):2409\u201321.","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"4993_CR7","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/s41572-019-0111-2","volume":"5","author":"N Harbeck","year":"2019","unstructured":"Harbeck N, Penault-Llorca F, Cortes J, Gnant M, Houssami N, Poortmans P, et al. Breast cancer. Nat Rev Dis Primers. 2019;5(1):66.","journal-title":"Nat Rev Dis Primers"},{"key":"4993_CR8","doi-asserted-by":"publisher","first-page":"121872","DOI":"10.1016\/j.biomaterials.2022.121872","volume":"291","author":"W Zhou","year":"2022","unstructured":"Zhou W, Lei S, Liu M, Li D, Huang Y, Hu X, et al. Injectable and photocurable CAR-T cell formulation enhances the anti-tumor activity to melanoma in mice. Biomaterials. 2022;291:121872.","journal-title":"Biomaterials"},{"key":"4993_CR9","doi-asserted-by":"publisher","first-page":"1101495","DOI":"10.3389\/fimmu.2023.1101495","volume":"14","author":"X Zhang","year":"2023","unstructured":"Zhang X, Zhang H, Lan H, Wu J, Xiao Y. CAR-T cell therapy in multiple myeloma: current limitations and potential strategies. Front Immunol. 2023;14:1101495.","journal-title":"Front Immunol"},{"issue":"19","key":"4993_CR10","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1097\/CM9.0000000000002549","volume":"136","author":"Z Yang","year":"2023","unstructured":"Yang Z, Wang Y. Clinical development of chimeric antigen receptor-T cell therapy for hematological malignancies. Chin Med J (Engl). 2023;136(19):2285\u201396.","journal-title":"Chin Med J (Engl)"},{"issue":"7","key":"4993_CR11","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.stem.2024.04.018","volume":"31","author":"TI Maulana","year":"2024","unstructured":"Maulana TI, Teufel C, Cipriano M, Roosz J, Lazarevski L, van den Hil FE, et al. Breast cancer-on-chip for patient-specific efficacy and safety testing of CAR-T cells. Cell Stem Cell. 2024;31(7):989-1002.e9.","journal-title":"Cell Stem Cell"},{"issue":"21","key":"4993_CR12","doi-asserted-by":"publisher","first-page":"3248","DOI":"10.1182\/bloodadvances.2019000703","volume":"3","author":"A Schmidts","year":"2019","unstructured":"Schmidts A, Ormh\u00f8j M, Choi BD, Taylor AO, Bouffard AA, Scarf\u00f2 I, et al. Rational design of a trimeric APRIL-based CAR-binding domain enables efficient targeting of multiple myeloma. Blood Adv. 2019;3(21):3248\u201360.","journal-title":"Blood Adv"},{"issue":"12","key":"4993_CR13","doi-asserted-by":"publisher","first-page":"2548","DOI":"10.7150\/ijbs.34213","volume":"15","author":"S Ma","year":"2019","unstructured":"Ma S, Li X, Wang X, Cheng L, Li Z, Zhang C, et al. Current progress in CAR-T cell therapy for solid tumors. Int J Biol Sci. 2019;15(12):2548\u201360.","journal-title":"Int J Biol Sci"},{"key":"4993_CR14","doi-asserted-by":"publisher","first-page":"111333","DOI":"10.1016\/j.biopha.2021.111333","volume":"137","author":"Z Xie","year":"2021","unstructured":"Xie Z, Shen J, Sun H, Li J, Wang X. Polymer-based hydrogels with local drug release for cancer immunotherapy. Biomed Pharmacother. 2021;137:111333.","journal-title":"Biomed Pharmacother"},{"key":"4993_CR15","doi-asserted-by":"publisher","first-page":"723490","DOI":"10.3389\/fbioe.2021.723490","volume":"9","author":"R Cui","year":"2021","unstructured":"Cui R, Wu Q, Wang J, Zheng X, Ou R, Xu Y, et al. Hydrogel-by-design: Smart delivery system for cancer immunotherapy. Front Bioeng Biotechnol. 2021;9:723490.","journal-title":"Front Bioeng Biotechnol"},{"issue":"2","key":"4993_CR16","first-page":"373","volume":"17","author":"Z Sun","year":"2020","unstructured":"Sun Z, Song C, Wang C, Hu Y, Wu J. Hydrogel-based controlled drug delivery for cancer treatment: A review. Mol Pharm. 2020;17(2):373\u201391.","journal-title":"Mol Pharm"},{"issue":"27","key":"4993_CR17","doi-asserted-by":"publisher","first-page":"e2301174","DOI":"10.1002\/adhm.202301174","volume":"12","author":"E Askari","year":"2023","unstructured":"Askari E, Shokrollahi Barough M, Rahmanian M, Mojtabavi N, Sarrami Forooshani R, Seyfoori A, et al. Cancer immunotherapy using bioengineered micro\/nano structured hydrogels. Adv Healthc Mater. 2023;12(27):e2301174.","journal-title":"Adv Healthc Mater"},{"issue":"14","key":"4993_CR18","doi-asserted-by":"publisher","first-page":"e2409835","DOI":"10.1002\/advs.202409835","volume":"12","author":"G Li","year":"2025","unstructured":"Li G, Du R, Wang D, Zhang X, Wang L, Pu S, et al. Improved efficacy of triple-negative breast cancer immunotherapy via hydrogel-based co-delivery of CAR-T cells and mitophagy agonist. Adv Sci (Weinh). 2025;12(14):e2409835.","journal-title":"Adv Sci (Weinh)"},{"issue":"21","key":"4993_CR19","doi-asserted-by":"publisher","first-page":"e2313188","DOI":"10.1002\/adma.202313188","volume":"36","author":"Y Peng","year":"2024","unstructured":"Peng Y, Liang S, Meng QF, Liu D, Ma K, Zhou M, et al. Engineered bio-based hydrogels for cancer immunotherapy. Adv Mater. 2024;36(21):e2313188.","journal-title":"Adv Mater"},{"issue":"2","key":"4993_CR20","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1188\/20.CJON.139-147","volume":"24","author":"B Corey","year":"2020","unstructured":"Corey B, Smania MA, Spotts H, Andersen M. Young women with breast cancer: treatment, care, and nursing implications. Clin J Oncol Nurs. 2020;24(2):139\u201347.","journal-title":"Clin J Oncol Nurs"},{"key":"4993_CR21","first-page":"1","volume":"42","author":"ME Tesch","year":"2022","unstructured":"Tesch ME, Partridge AH. Treatment of breast cancer in young adults. Am Soc Clin Oncol Educ Book. 2022;42:1\u201312.","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"4993_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/genes13060960","author":"J Ben-Dror","year":"2022","unstructured":"Ben-Dror J, Shalamov M, Sonnenblick A. The history of early breast cancer treatment. Genes (Basel). 2022. https:\/\/doi.org\/10.3390\/genes13060960.","journal-title":"Genes (Basel)"},{"issue":"7913","key":"4993_CR23","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/s41586-022-04735-9","volume":"606","author":"M \u0141uksza","year":"2022","unstructured":"\u0141uksza M, Sethna ZM, Rojas LA, Lihm J, Bravi B, Elhanati Y, et al. Neoantigen quality predicts immunoediting in survivors of pancreatic cancer. Nature. 2022;606(7913):389\u201395.","journal-title":"Nature"},{"key":"4993_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/genes13091593","author":"C Criscitiello","year":"2022","unstructured":"Criscitiello C, Corti C. Breast cancer genetics: diagnostics and treatment. Genes. 2022. https:\/\/doi.org\/10.3390\/genes13091593.","journal-title":"Genes"},{"issue":"5","key":"4993_CR25","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.21037\/apm-24-64","volume":"13","author":"S Vuong","year":"2024","unstructured":"Vuong S, Warner E. Breast cancer survivorship among younger patients: challenges and opportunities-narrative review. Ann Palliat Med. 2024;13(5):1246\u201357.","journal-title":"Ann Palliat Med"},{"issue":"12","key":"4993_CR26","first-page":"1381","volume":"28","author":"M Unar-Mungu\u00eda","year":"2017","unstructured":"Unar-Mungu\u00eda M, Meza R, Colchero MA, Torres-Mej\u00eda G, de Cos\u00edo TG. Economic and disease burden of breast cancer associated with suboptimal breastfeeding practices in Mexico. Cancer Causes Control. 2017;28(12):1381\u201391.","journal-title":"Cancer Causes Control"},{"issue":"1","key":"4993_CR27","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41392-024-02108-4","volume":"10","author":"X Xiong","year":"2025","unstructured":"Xiong X, Zheng LW, Ding Y, Chen YF, Cai YW, Wang LP, et al. Breast cancer: pathogenesis and treatments. Signal Transduct Target Ther. 2025;10(1):49.","journal-title":"Signal Transduct Target Ther"},{"issue":"12","key":"4993_CR28","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1016\/j.tcb.2017.09.001","volume":"27","author":"A L\u00f3pez-Soto","year":"2017","unstructured":"L\u00f3pez-Soto A, Gonzalez S, L\u00f3pez-Larrea C, Kroemer G. Immunosurveillance of malignant cells with complex karyotypes. Trends Cell Biol. 2017;27(12):880\u20134.","journal-title":"Trends Cell Biol"},{"issue":"2","key":"4993_CR29","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/s41577-023-00911-8","volume":"24","author":"KM Ashby","year":"2024","unstructured":"Ashby KM, Hogquist KA. A guide to thymic selection of T cells. Nat Rev Immunol. 2024;24(2):103\u201317.","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"4993_CR30","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1038\/nri3173","volume":"12","author":"NP Weng","year":"2012","unstructured":"Weng NP, Araki Y, Subedi K. The molecular basis of the memory T cell response: differential gene expression and its epigenetic regulation. Nat Rev Immunol. 2012;12(4):306\u201315.","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"4993_CR31","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s00018-017-2597-7","volume":"75","author":"R Seelige","year":"2018","unstructured":"Seelige R, Searles S, Bui JD. Mechanisms regulating immune surveillance of cellular stress in cancer. Cell Mol Life Sci. 2018;75(2):225\u201340.","journal-title":"Cell Mol Life Sci"},{"issue":"9","key":"4993_CR32","doi-asserted-by":"publisher","first-page":"2454","DOI":"10.1016\/j.cell.2021.03.023","volume":"184","author":"E Gangoso","year":"2021","unstructured":"Gangoso E, Southgate B, Bradley L, Rus S, Galvez-Cancino F, McGivern N, et al. Glioblastomas acquire myeloid-affiliated transcriptional programs via epigenetic immunoediting to elicit immune evasion. Cell. 2021;184(9):2454-70.e26.","journal-title":"Cell"},{"issue":"1","key":"4993_CR33","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1186\/s12935-021-01979-9","volume":"21","author":"Z Liu","year":"2021","unstructured":"Liu Z, Hu S, Yun Z, Hu W, Zhang S, Luo D. Using dynamic cell communication improves treatment strategies of breast cancer. Cancer Cell Int. 2021;21(1):275.","journal-title":"Cancer Cell Int"},{"issue":"6670","key":"4993_CR34","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1126\/science.adh4124","volume":"382","author":"ME Badr","year":"2023","unstructured":"Badr ME, Zhang Z, Tai X, Singer A. CD8 T cell tolerance results from eviction of immature autoreactive cells from the thymus. Science. 2023;382(6670):534\u201341.","journal-title":"Science"},{"issue":"1","key":"4993_CR35","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1158\/0008-5472.CAN-21-2362","volume":"82","author":"W Jing","year":"2022","unstructured":"Jing W, Wang G, Cui Z, Xiong G, Jiang X, Li Y, et al. FGFR3 destabilizes PD-L1 via NEDD4 to control T-cell-mediated bladder cancer immune surveillance. Cancer Res. 2022;82(1):114\u201329.","journal-title":"Cancer Res"},{"key":"4993_CR36","doi-asserted-by":"publisher","first-page":"589641","DOI":"10.3389\/fimmu.2020.589641","volume":"11","author":"S N\u00fcssing","year":"2020","unstructured":"N\u00fcssing S, Trapani JA, Parish IA. Revisiting T cell tolerance as a checkpoint target for cancer immunotherapy. Front Immunol. 2020;11:589641.","journal-title":"Front Immunol"},{"issue":"6","key":"4993_CR37","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1016\/j.cmet.2021.04.001","volume":"33","author":"Y Liu","year":"2021","unstructured":"Liu Y, Liang G, Xu H, Dong W, Dong Z, Qiu Z, et al. Tumors exploit FTO-mediated regulation of glycolytic metabolism to evade immune surveillance. Cell Metab. 2021;33(6):1221-33.e11.","journal-title":"Cell Metab"},{"issue":"1","key":"4993_CR38","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1186\/s12885-018-4441-3","volume":"18","author":"JP Bates","year":"2018","unstructured":"Bates JP, Derakhshandeh R, Jones L, Webb TJ. Mechanisms of immune evasion in breast cancer. BMC Cancer. 2018;18(1):556.","journal-title":"BMC Cancer"},{"issue":"2","key":"4993_CR39","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.it.2013.10.001","volume":"35","author":"A Schietinger","year":"2014","unstructured":"Schietinger A, Greenberg PD. Tolerance and exhaustion: defining mechanisms of T cell dysfunction. Trends Immunol. 2014;35(2):51\u201360.","journal-title":"Trends Immunol"},{"issue":"5","key":"4993_CR40","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1042\/CBI20090206","volume":"34","author":"SK Bhutia","year":"2010","unstructured":"Bhutia SK, Mallick SK, Maiti TK. Tumour escape mechanisms and their therapeutic implications in combination tumour therapy. Cell Biol Int. 2010;34(5):553\u201363.","journal-title":"Cell Biol Int"},{"key":"4993_CR41","doi-asserted-by":"publisher","first-page":"927153","DOI":"10.3389\/fimmu.2022.927153","volume":"13","author":"X Zhang","year":"2022","unstructured":"Zhang X, Zhu L, Zhang H, Chen S, Xiao Y. CAR-T cell therapy in hematological malignancies: current opportunities and challenges. Front Immunol. 2022;13:927153.","journal-title":"Front Immunol"},{"issue":"4","key":"4993_CR42","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","volume":"11","author":"RC Sterner","year":"2021","unstructured":"Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021;11(4):69.","journal-title":"Blood Cancer J"},{"key":"4993_CR43","doi-asserted-by":"publisher","first-page":"1188049","DOI":"10.3389\/fimmu.2023.1188049","volume":"14","author":"A Mitra","year":"2023","unstructured":"Mitra A, Barua A, Huang L, Ganguly S, Feng Q, He B. From bench to bedside: the history and progress of CAR T cell therapy. Front Immunol. 2023;14:1188049.","journal-title":"Front Immunol"},{"issue":"2","key":"4993_CR44","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.jaip.2021.10.037","volume":"10","author":"J Wat","year":"2022","unstructured":"Wat J, Barmettler S. Hypogammaglobulinemia after chimeric antigen receptor (CAR) T-Cell therapy: Characteristics, management, and future directions. J Allergy Clin Immunol Pract. 2022;10(2):460\u20136.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"4993_CR45","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s40164-023-00437-8","volume":"12","author":"WK Chan","year":"2023","unstructured":"Chan WK, Williams J, Sorathia K, Pray B, Abusaleh K, Bian Z, et al. A novel CAR-T cell product targeting CD74 is an effective therapeutic approach in preclinical mantle cell lymphoma models. Exp Hematol Oncol. 2023;12(1):79.","journal-title":"Exp Hematol Oncol"},{"key":"4993_CR46","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.jaut.2018.08.004","volume":"96","author":"L Zhang","year":"2019","unstructured":"Zhang L, Sosinowski T, Cox AR, Cepeda JR, Sekhar NS, Hartig SM, et al. Chimeric antigen receptor (CAR) T cells targeting a pathogenic MHC class II:peptide complex modulate the progression of autoimmune diabetes. J Autoimmun. 2019;96:50\u20138.","journal-title":"J Autoimmun"},{"issue":"1","key":"4993_CR47","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1186\/s13287-024-03783-4","volume":"15","author":"F Sani","year":"2024","unstructured":"Sani F, Shojaei S, Tabatabaei SA, Khorraminejad-Shirazi M, Latifi M, Sani M, et al. CAR-T cell-derived exosomes: a new perspective for cancer therapy. Stem Cell Res Ther. 2024;15(1):174.","journal-title":"Stem Cell Res Ther"},{"issue":"5","key":"4993_CR48","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1007\/s10875-012-9689-9","volume":"32","author":"S Wilkie","year":"2012","unstructured":"Wilkie S, van Schalkwyk MC, Hobbs S, Davies DM, van der Stegen SJ, Pereira AC, et al. Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling. J Clin Immunol. 2012;32(5):1059\u201370.","journal-title":"J Clin Immunol"},{"issue":"11","key":"4993_CR49","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1038\/s41551-022-00915-0","volume":"6","author":"SJC van der Stegen","year":"2022","unstructured":"van der Stegen SJC, Lindenbergh PL, Petrovic RM, Xie H, Diop MP, Alexeeva V, et al. Generation of T-cell-receptor-negative CD8\u03b1\u03b2-positive CAR T cells from T-cell-derived induced pluripotent stem cells. Nat Biomed Eng. 2022;6(11):1284\u201397.","journal-title":"Nat Biomed Eng"},{"issue":"9","key":"4993_CR50","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1182\/blood.2024024523","volume":"144","author":"CJ Nicolai","year":"2024","unstructured":"Nicolai CJ, Parker MH, Qin J, Tang W, Ulrich-Lewis JT, Gottschalk RJ, et al. In vivo CAR T-cell generation in nonhuman primates using lentiviral vectors displaying a multidomain fusion ligand. Blood. 2024;144(9):977\u201387.","journal-title":"Blood"},{"issue":"2","key":"4993_CR51","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/mt.2009.210","volume":"18","author":"XS Zhong","year":"2010","unstructured":"Zhong XS, Matsushita M, Plotkin J, Riviere I, Sadelain M. Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase\/AKT\/Bcl-XL activation and CD8+ T cell-mediated tumor eradication. Mol Ther. 2010;18(2):413\u201320.","journal-title":"Mol Ther"},{"key":"4993_CR52","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20230903","author":"M Ayala Ceja","year":"2024","unstructured":"Ayala Ceja M, Khericha M, Harris CM, Puig-Saus C, Chen YY. CAR-T cell manufacturing: major process parameters and next-generation strategies. J Exp Med. 2024. https:\/\/doi.org\/10.1084\/jem.20230903.","journal-title":"J Exp Med"},{"issue":"3","key":"4993_CR53","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1007\/s00262-020-02735-0","volume":"70","author":"J Qu","year":"2021","unstructured":"Qu J, Mei Q, Chen L, Zhou J. Chimeric antigen receptor (CAR)-T-cell therapy in non-small-cell lung cancer (NSCLC): Current status and future perspectives. Cancer Immunol Immunother. 2021;70(3):619\u201331.","journal-title":"Cancer Immunol Immunother"},{"issue":"3","key":"4993_CR54","doi-asserted-by":"publisher","first-page":"210","DOI":"10.3343\/alm.2023.0388","volume":"44","author":"SJ Kim","year":"2024","unstructured":"Kim SJ, Yoon SE, Kim WS. Current challenges in Chimeric Antigen Receptor T-cell therapy in patients with B-cell Lymphoid Malignancies. Ann Lab Med. 2024;44(3):210\u201321.","journal-title":"Ann Lab Med"},{"issue":"82","key":"4993_CR55","doi-asserted-by":"publisher","first-page":"eabq3016","DOI":"10.1126\/sciimmunol.abq3016","volume":"8","author":"JJ Peng","year":"2023","unstructured":"Peng JJ, Wang L, Li Z, Ku CL, Ho PC. Metabolic challenges and interventions in CAR T cell therapy. Sci Immunol. 2023;8(82):eabq3016.","journal-title":"Sci Immunol"},{"issue":"8","key":"4993_CR56","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1038\/mt.2013.110","volume":"21","author":"S Kakarla","year":"2013","unstructured":"Kakarla S, Chow KK, Mata M, Shaffer DR, Song XT, Wu MF, et al. Antitumor effects of chimeric receptor engineered human T cells directed to tumor stroma. Mol Ther. 2013;21(8):1611\u201320.","journal-title":"Mol Ther"},{"issue":"1","key":"4993_CR57","doi-asserted-by":"publisher","first-page":"5110","DOI":"10.1038\/s41467-023-40850-5","volume":"14","author":"Z Xiao","year":"2023","unstructured":"Xiao Z, Todd L, Huang L, Noguera-Ortega E, Lu Z, Huang L, et al. Desmoplastic stroma restricts T cell extravasation and mediates immune exclusion and immunosuppression in solid tumors. Nat Commun. 2023;14(1):5110.","journal-title":"Nat Commun"},{"issue":"11","key":"4993_CR58","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1038\/s41587-023-02060-8","volume":"42","author":"Y Zhao","year":"2024","unstructured":"Zhao Y, Chen J, Andreatta M, Feng B, Xie YQ, Wenes M, et al. IL-10-expressing CAR T cells resist dysfunction and mediate durable clearance of solid tumors and metastases. Nat Biotechnol. 2024;42(11):1693\u2013704.","journal-title":"Nat Biotechnol"},{"issue":"6","key":"4993_CR59","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1038\/s41590-021-00940-2","volume":"22","author":"Y Guo","year":"2021","unstructured":"Guo Y, Xie YQ, Gao M, Zhao Y, Franco F, Wenes M, et al. Metabolic reprogramming of terminally exhausted CD8(+) T cells by IL-10 enhances anti-tumor immunity. Nat Immunol. 2021;22(6):746\u201356.","journal-title":"Nat Immunol"},{"issue":"7","key":"4993_CR60","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1016\/j.ymthe.2018.05.003","volume":"26","author":"CC Kloss","year":"2018","unstructured":"Kloss CC, Lee J, Zhang A, Chen F, Melenhorst JJ, Lacey SF, et al. Dominant-negative TGF-\u03b2 receptor enhances PSMA-targeted human CAR T cell proliferation and augments prostate cancer eradication. Mol Ther. 2018;26(7):1855\u201366.","journal-title":"Mol Ther"},{"issue":"12","key":"4993_CR61","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1016\/j.bcp.2007.08.025","volume":"74","author":"YC Huang","year":"2007","unstructured":"Huang YC, Hsiao YC, Chen YJ, Wei YY, Lai TH, Tang CH. Stromal cell-derived factor-1 enhances motility and integrin up-regulation through CXCR4, ERK and NF-kappaB-dependent pathway in human lung cancer cells. Biochem Pharmacol. 2007;74(12):1702\u201312.","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"4993_CR62","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/imr.12125","volume":"257","author":"M Chmielewski","year":"2014","unstructured":"Chmielewski M, Hombach AA, Abken H. Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma. Immunol Rev. 2014;257(1):83\u201390.","journal-title":"Immunol Rev"},{"issue":"11","key":"4993_CR63","doi-asserted-by":"publisher","first-page":"3193","DOI":"10.1016\/j.ymthe.2023.09.010","volume":"31","author":"R Sun","year":"2023","unstructured":"Sun R, Sun Y, Wu C, Liu Y, Zhou M, Dong Y, et al. CXCR4-modified CAR-T cells suppresses MDSCs recruitment via STAT3\/NF-\u03baB\/SDF-1\u03b1 axis to enhance efficacy against pancreatic cancer. Mol Ther. 2023;31(11):3193\u2013209.","journal-title":"Mol Ther"},{"issue":"21","key":"4993_CR64","doi-asserted-by":"publisher","first-page":"9891","DOI":"10.1158\/0008-5472.CAN-05-1293","volume":"65","author":"P Kukreja","year":"2005","unstructured":"Kukreja P, Abdel-Mageed AB, Mondal D, Liu K, Agrawal KC. Up-regulation of CXCR4 expression in PC-3 cells by stromal-derived factor-1alpha (CXCL12) increases endothelial adhesion and transendothelial migration: role of MEK\/ERK signaling pathway-dependent NF-kappaB activation. Cancer Res. 2005;65(21):9891\u20138.","journal-title":"Cancer Res"},{"issue":"1","key":"4993_CR65","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1002\/jcp.21846","volume":"221","author":"CY Huang","year":"2009","unstructured":"Huang CY, Lee CY, Chen MY, Yang WH, Chen YH, Chang CH, et al. Stromal cell-derived factor-1\/CXCR4 enhanced motility of human osteosarcoma cells involves MEK1\/2, ERK and NF-kappaB-dependent pathways. J Cell Physiol. 2009;221(1):204\u201312.","journal-title":"J Cell Physiol"},{"key":"4993_CR66","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abi5781","author":"BL Cadilha","year":"2021","unstructured":"Cadilha BL, Benmebarek MR, Dorman K, Oner A, Lorenzini T, Obeck H, et al. Combined tumor-directed recruitment and protection from immune suppression enable CAR T cell efficacy in solid tumors. Sci Adv. 2021. https:\/\/doi.org\/10.1126\/sciadv.abi5781.","journal-title":"Sci Adv"},{"key":"4993_CR67","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000676","author":"T St\u00fcber","year":"2020","unstructured":"St\u00fcber T, Monjezi R, Wallstabe L, K\u00fchnemundt J, Nietzer SL, Dandekar G, et al. Inhibition of TGF-\u03b2-receptor signaling augments the antitumor function of ROR1-specific CAR T-cells against triple-negative breast cancer. J Immunother Cancer. 2020. https:\/\/doi.org\/10.1136\/jitc-2020-000676.","journal-title":"J Immunother Cancer"},{"issue":"5","key":"4993_CR68","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/nm.3833","volume":"21","author":"I Caruana","year":"2015","unstructured":"Caruana I, Savoldo B, Hoyos V, Weber G, Liu H, Kim ES, et al. Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes. Nat Med. 2015;21(5):524\u20139.","journal-title":"Nat Med"},{"issue":"4","key":"4993_CR69","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.ccell.2020.07.005","volume":"38","author":"M Hong","year":"2020","unstructured":"Hong M, Clubb JD, Chen YY. Engineering CAR-T cells for next-generation cancer therapy. Cancer Cell. 2020;38(4):473\u201388.","journal-title":"Cancer Cell"},{"key":"4993_CR70","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14040978","author":"LG White","year":"2022","unstructured":"White LG, Goy HE, Rose AJ, McLellan AD. Controlling cell trafficking: addressing failures in CAR T and NK cell therapy of solid tumours. Cancers (Basel). 2022. https:\/\/doi.org\/10.3390\/cancers14040978.","journal-title":"Cancers (Basel)"},{"issue":"15","key":"4993_CR71","doi-asserted-by":"publisher","first-page":"5019","DOI":"10.1002\/cam4.4064","volume":"10","author":"HE Marei","year":"2021","unstructured":"Marei HE, Althani A, Afifi N, Hasan A, Caceci T, Pozzoli G, et al. Current progress in chimeric antigen receptor t cell therapy for glioblastoma multiforme. Cancer Med. 2021;10(15):5019\u201330.","journal-title":"Cancer Med"},{"key":"4993_CR72","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.canlet.2020.04.008","volume":"484","author":"\u00c1 Sz\u00f6\u0151r","year":"2020","unstructured":"Sz\u00f6\u0151r \u00c1, T\u00f3th G, Zsebik B, Szab\u00f3 V, Eshhar Z, Abken H, et al. Trastuzumab derived HER2-specific CARs for the treatment of trastuzumab-resistant breast cancer: CAR t cells penetrate and eradicate tumors that are not accessible to antibodies. Cancer Lett. 2020;484:1\u20138.","journal-title":"Cancer Lett"},{"issue":"4","key":"4993_CR73","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1002\/JLB.1MR0520-746R","volume":"108","author":"E Donnadieu","year":"2020","unstructured":"Donnadieu E, Dupr\u00e9 L, Pinho LG, Cotta-de-Almeida V. Surmounting the obstacles that impede effective CAR t cell trafficking to solid tumors. J Leukoc Biol. 2020;108(4):1067\u201379.","journal-title":"J Leukoc Biol"},{"key":"4993_CR74","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20200844","author":"N Xu","year":"2021","unstructured":"Xu N, Palmer DC, Robeson AC, Shou P, Bommiasamy H, Laurie SJ, et al. STING agonist promotes CAR T cell trafficking and persistence in breast cancer. J Exp Med. 2021. https:\/\/doi.org\/10.1084\/jem.20200844.","journal-title":"J Exp Med"},{"issue":"2","key":"4993_CR75","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.pan.2019.01.015","volume":"19","author":"L Qian","year":"2019","unstructured":"Qian L, Yu S, Yin C, Zhu B, Chen Z, Meng Z, et al. Plasma IFN-\u03b3-inducible chemokines CXCL9 and CXCL10 correlate with survival and chemotherapeutic efficacy in advanced pancreatic ductal adenocarcinoma. Pancreatology. 2019;19(2):340\u20135.","journal-title":"Pancreatology"},{"issue":"22","key":"4993_CR76","doi-asserted-by":"publisher","first-page":"5458","DOI":"10.1158\/1078-0432.CCR-10-0712","volume":"16","author":"W Peng","year":"2010","unstructured":"Peng W, Ye Y, Rabinovich BA, Liu C, Lou Y, Zhang M, et al. Transduction of tumor-specific t cells with CXCR2 chemokine receptor improves migration to tumor and antitumor immune responses. Clin Cancer Res. 2010;16(22):5458\u201368.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"4993_CR77","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1093\/neuonc\/noae126","volume":"26","author":"AJ Hou","year":"2024","unstructured":"Hou AJ, Shih RM, Uy BR, Shafer A, Chang ZL, Comin-Anduix B, et al. IL-13R\u03b12\/TGF-\u03b2 bispecific CAR-T cells counter TGF-\u03b2-mediated immune suppression and potentiate anti-tumor responses in glioblastoma. Neuro Oncol. 2024;26(10):1850\u201366.","journal-title":"Neuro Oncol"},{"key":"4993_CR78","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.133977","author":"N Tang","year":"2020","unstructured":"Tang N, Cheng C, Zhang X, Qiao M, Li N, Mu W, et al. TGF-\u03b2 inhibition via CRISPR promotes the long-term efficacy of CAR T cells against solid tumors. JCI Insight. 2020. https:\/\/doi.org\/10.1172\/jci.insight.133977.","journal-title":"JCI Insight"},{"key":"4993_CR79","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s40425-017-0222-9","volume":"5","author":"KM Hege","year":"2017","unstructured":"Hege KM, Bergsland EK, Fisher GA, Nemunaitis JJ, Warren RS, McArthur JG, et al. Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer. J Immunother Cancer. 2017;5:22.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"4993_CR80","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.ymthe.2020.09.034","volume":"29","author":"R Sun","year":"2021","unstructured":"Sun R, Luo H, Su J, Di S, Zhou M, Shi B, et al. Olaparib suppresses MDSC recruitment via SDF1\u03b1\/CXCR4 axis to improve the anti-tumor efficacy of CAR-T cells on breast cancer in mice. Mol Ther. 2021;29(1):60\u201374.","journal-title":"Mol Ther"},{"issue":"7","key":"4993_CR81","first-page":"571","volume":"21","author":"J Mou","year":"2024","unstructured":"Mou J, Li C, Zheng Q, Meng X, Tang H. Research progress in tumor angiogenesis and drug resistance in breast cancer. Cancer Biol Med. 2024;21(7):571\u201385.","journal-title":"Cancer Biol Med"},{"issue":"1","key":"4993_CR82","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1158\/1078-0432.CCR-17-2041","volume":"24","author":"SJ Priceman","year":"2018","unstructured":"Priceman SJ, Tilakawardane D, Jeang B, Aguilar B, Murad JP, Park AK, et al. Regional delivery of chimeric antigen receptor-engineered T Cells effectively targets HER2(+) breast cancer metastasis to the brain. Clin Cancer Res. 2018;24(1):95\u2013105.","journal-title":"Clin Cancer Res"},{"key":"4993_CR83","doi-asserted-by":"publisher","first-page":"135039","DOI":"10.1155\/2011\/135039","volume":"2011","author":"A Lorico","year":"2011","unstructured":"Lorico A, Rappa G. Phenotypic heterogeneity of breast cancer stem cells. J Oncol. 2011;2011:135039.","journal-title":"J Oncol"},{"key":"4993_CR84","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.semcancer.2019.12.019","volume":"65","author":"S Gomez","year":"2020","unstructured":"Gomez S, Tabernacki T, Kobyra J, Roberts P, Chiappinelli KB. Combining epigenetic and immune therapy to overcome cancer resistance. Semin Cancer Biol. 2020;65:99\u2013113.","journal-title":"Semin Cancer Biol"},{"issue":"1","key":"4993_CR85","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1186\/s13287-021-02321-w","volume":"12","author":"K Song","year":"2021","unstructured":"Song K, Farzaneh M. Signaling pathways governing breast cancer stem cells behavior. Stem Cell Res Ther. 2021;12(1):245.","journal-title":"Stem Cell Res Ther"},{"key":"4993_CR86","doi-asserted-by":"publisher","first-page":"1356913","DOI":"10.3389\/fimmu.2024.1356913","volume":"15","author":"X Chen","year":"2024","unstructured":"Chen X, Ik S, Yang M, Tu J, Yuan X. MUC1 and MUC16: critical for immune modulation in cancer therapeutics. Front Immunol. 2024;15:1356913.","journal-title":"Front Immunol"},{"issue":"1","key":"4993_CR87","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.bbrc.2014.09.069","volume":"453","author":"S Kotiyal","year":"2014","unstructured":"Kotiyal S, Bhattacharya S. Breast cancer stem cells, EMT and therapeutic targets. Biochem Biophys Res Commun. 2014;453(1):112\u20136.","journal-title":"Biochem Biophys Res Commun"},{"key":"4993_CR88","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aau7746","author":"EL Smith","year":"2019","unstructured":"Smith EL, Harrington K, Staehr M, Masakayan R, Jones J, Long TJ, et al. GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells. Sci Transl Med. 2019. https:\/\/doi.org\/10.1126\/scitranslmed.aau7746.","journal-title":"Sci Transl Med"},{"issue":"8","key":"4993_CR89","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1038\/s41591-021-01436-0","volume":"27","author":"JY Spiegel","year":"2021","unstructured":"Spiegel JY, Patel S, Muffly L, Hossain NM, Oak J, Baird JH, et al. CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial. Nat Med. 2021;27(8):1419\u201331.","journal-title":"Nat Med"},{"key":"4993_CR90","doi-asserted-by":"crossref","unstructured":"Bajor M, Graczyk-Jarzynka A, Marhelava K, Burdzinska A, Muchowicz A, Goral A, et al. PD-L1 CAR effector cells induce self-amplifying cytotoxic effects against target cells. J Immunother Cancer. 2022;10(1).","DOI":"10.1136\/jitc-2021-002500"},{"key":"4993_CR91","doi-asserted-by":"publisher","first-page":"1380065","DOI":"10.3389\/fimmu.2024.1380065","volume":"15","author":"KM Chen","year":"2024","unstructured":"Chen KM, Grun D, Gautier B, Venkatesha S, Maddox M, Zhang AH, et al. Targeting PD-L1 in solid cancer with myeloid cells expressing a CAR-like immune receptor. Front Immunol. 2024;15:1380065.","journal-title":"Front Immunol"},{"issue":"11","key":"4993_CR92","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1038\/mt.2013.185","volume":"21","author":"M Hegde","year":"2013","unstructured":"Hegde M, Corder A, Chow KK, Mukherjee M, Ashoori A, Kew Y, et al. Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma. Mol Ther. 2013;21(11):2087\u2013101.","journal-title":"Mol Ther"},{"issue":"7","key":"4993_CR93","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1016\/j.cell.2023.03.007","volume":"186","author":"D Hirschhorn","year":"2023","unstructured":"Hirschhorn D, Budhu S, Kraehenbuehl L, Gigoux M, Schr\u00f6der D, Chow A, et al. T cell immunotherapies engage neutrophils to eliminate tumor antigen escape variants. Cell. 2023;186(7):1432-47.e17.","journal-title":"Cell"},{"issue":"7750","key":"4993_CR94","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/s41586-019-1054-1","volume":"568","author":"M Hamieh","year":"2019","unstructured":"Hamieh M, Dobrin A, Cabriolu A, van der Stegen SJC, Giavridis T, Mansilla-Soto J, et al. CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape. Nature. 2019;568(7750):112\u20136.","journal-title":"Nature"},{"key":"4993_CR95","doi-asserted-by":"publisher","first-page":"117252","DOI":"10.1016\/j.biopha.2024.117252","volume":"178","author":"H Lin","year":"2024","unstructured":"Lin H, Yang X, Ye S, Huang L, Mu W. Antigen escape in CAR-T cell therapy: mechanisms and overcoming strategies. Biomed Pharmacother. 2024;178:117252.","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"4993_CR96","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s12943-025-02334-6","volume":"24","author":"Y Lu","year":"2025","unstructured":"Lu Y, Zhao F. Strategies to overcome tumour relapse caused by antigen escape after CAR T therapy. Mol Cancer. 2025;24(1):126.","journal-title":"Mol Cancer"},{"issue":"7","key":"4993_CR97","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1182\/blood-2017-05-781351","volume":"131","author":"L Lee","year":"2018","unstructured":"Lee L, Draper B, Chaplin N, Philip B, Chin M, Galas-Filipowicz D, et al. An APRIL-based chimeric antigen receptor for dual targeting of BCMA and TACI in multiple myeloma. Blood. 2018;131(7):746\u201358.","journal-title":"Blood"},{"key":"4993_CR98","doi-asserted-by":"crossref","unstructured":"Zhang B, Wu J, Jiang H, Zhou M. Strategies to Overcome Antigen Heterogeneity in CAR-T Cell Therapy. Cells. 2025;14(5).","DOI":"10.3390\/cells14050320"},{"issue":"4","key":"4993_CR99","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/s43018-023-00536-9","volume":"4","author":"F Cattaruzza","year":"2023","unstructured":"Cattaruzza F, Nazeer A, To M, Hammond M, Koski C, Liu LY, et al. Precision-activated T-cell engagers targeting HER2 or EGFR and CD3 mitigate on-target, off-tumor toxicity for immunotherapy in solid tumors. Nat Cancer. 2023;4(4):485\u2013501.","journal-title":"Nat Cancer"},{"issue":"1","key":"4993_CR100","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","volume":"15","author":"SS Neelapu","year":"2018","unstructured":"Neelapu SS, Tummala S, Kebriaei P, Wierda W, Gutierrez C, Locke FL, et al. Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. Nat Rev Clin Oncol. 2018;15(1):47\u201362.","journal-title":"Nat Rev Clin Oncol"},{"issue":"22","key":"4993_CR101","doi-asserted-by":"publisher","first-page":"4288","DOI":"10.1158\/0008-5472.CAN-21-2483","volume":"82","author":"LM Boustany","year":"2022","unstructured":"Boustany LM, LaPorte SL, Wong L, White C, Vinod V, Shen J, et al. A probody T cell-engaging bispecific antibody targeting EGFR and CD3 inhibits colon cancer growth with limited toxicity. Cancer Res. 2022;82(22):4288\u201398.","journal-title":"Cancer Res"},{"issue":"5","key":"4993_CR102","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1097\/CCO.0000000000000869","volume":"34","author":"PA Baeuerle","year":"2022","unstructured":"Baeuerle PA, Wesche H. T-cell-engaging antibodies for the treatment of solid tumors: challenges and opportunities. Curr Opin Oncol. 2022;34(5):552\u20138.","journal-title":"Curr Opin Oncol"},{"key":"4993_CR103","doi-asserted-by":"crossref","unstructured":"Montisci A, Vietri MT, Palmieri V, Sala S, Donatelli F, Napoli C. Cardiac Toxicity Associated with Cancer Immunotherapy and Biological Drugs. Cancers (Basel). 2021;13(19).","DOI":"10.3390\/cancers13194797"},{"key":"4993_CR104","doi-asserted-by":"crossref","unstructured":"Toribio-Garc\u00eda I, Olivares-Hern\u00e1ndez A, Miramontes-Gonz\u00e1lez JP, Dom\u00ednguez LP, Mart\u00edn Garc\u00eda A, Eiros Bachiller R, et al. Cardiotoxicity Secondary to Immune Checkpoint Inhibitors in the Elderly: Safety in Real-World Data. Cancers (Basel). 2023;15(17).","DOI":"10.3390\/cancers15174293"},{"key":"4993_CR105","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/978-3-030-79308-1_14","volume":"1342","author":"M Altan","year":"2021","unstructured":"Altan M, Zhong L, Shannon VR, Sheshadri A. Pulmonary toxicities of immunotherapy. Adv Exp Med Biol. 2021;1342:357\u201375.","journal-title":"Adv Exp Med Biol"},{"issue":"2","key":"4993_CR106","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.ccm.2016.12.012","volume":"38","author":"JD Possick","year":"2017","unstructured":"Possick JD. Pulmonary toxicities from checkpoint immunotherapy for malignancy. Clin Chest Med. 2017;38(2):223\u201332.","journal-title":"Clin Chest Med"},{"issue":"3","key":"4993_CR107","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.cell.2019.06.014","volume":"178","author":"DW Vredevoogd","year":"2019","unstructured":"Vredevoogd DW, Kuilman T, Ligtenberg MA, Boshuizen J, Stecker KE, de Bruijn B, et al. Augmenting immunotherapy impact by lowering tumor TNF cytotoxicity threshold. Cell. 2019;178(3):585-99.e15.","journal-title":"Cell"},{"issue":"9","key":"4993_CR108","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1038\/s41591-019-0549-5","volume":"25","author":"S Ghorashian","year":"2019","unstructured":"Ghorashian S, Kramer AM, Onuoha S, Wright G, Bartram J, Richardson R, et al. Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR. Nat Med. 2019;25(9):1408\u201314.","journal-title":"Nat Med"},{"issue":"1","key":"4993_CR109","doi-asserted-by":"publisher","first-page":"3552","DOI":"10.1038\/s41467-024-47799-z","volume":"15","author":"I Andreu-Saumell","year":"2024","unstructured":"Andreu-Saumell I, Rodriguez-Garcia A, M\u00fchlgrabner V, Gimenez-Alejandre M, Marzal B, Castellsagu\u00e9 J, et al. CAR affinity modulates the sensitivity of CAR-T cells to PD-1\/PD-L1-mediated inhibition. Nat Commun. 2024;15(1):3552.","journal-title":"Nat Commun"},{"key":"4993_CR110","doi-asserted-by":"crossref","unstructured":"Shabaneh TB, Stevens AR, Stull SM, Shimp KR, Seaton BW, Gad EA, et al. Systemically administered low-affinity HER2 CAR T cells mediate antitumor efficacy without toxicity. J Immunother Cancer. 2024;12(2).","DOI":"10.1136\/jitc-2023-008566"},{"issue":"1","key":"4993_CR111","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s12943-024-01952-w","volume":"23","author":"Y Wang","year":"2024","unstructured":"Wang Y, Buck A, Piel B, Zerefa L, Murugan N, Coherd CD, et al. Affinity fine-tuning anti-CAIX CAR-T cells mitigate on-target off-tumor side effects. Mol Cancer. 2024a;23(1):56.","journal-title":"Mol Cancer"},{"issue":"12","key":"4993_CR112","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1038\/s41551-024-01258-8","volume":"8","author":"Z Xia","year":"2024","unstructured":"Xia Z, Jin Q, Long Z, He Y, Liu F, Sun C, et al. Targeting overexpressed antigens in glioblastoma via CAR T cells with computationally designed high-affinity protein binders. Nat Biomed Eng. 2024;8(12):1634\u201350.","journal-title":"Nat Biomed Eng"},{"issue":"1","key":"4993_CR113","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1007\/s00018-021-04089-x","volume":"79","author":"Y Duan","year":"2021","unstructured":"Duan Y, Chen R, Huang Y, Meng X, Chen J, Liao C, et al. Tuning the ignition of CAR: optimizing the affinity of scFv to improve CAR-T therapy. Cell Mol Life Sci. 2021;79(1):14.","journal-title":"Cell Mol Life Sci"},{"issue":"1","key":"4993_CR114","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1038\/s41467-020-20785-x","volume":"12","author":"B Moghimi","year":"2021","unstructured":"Moghimi B, Muthugounder S, Jambon S, Tibbetts R, Hung L, Bassiri H, et al. Preclinical assessment of the efficacy and specificity of GD2-B7H3 SynNotch CAR-T in metastatic neuroblastoma. Nat Commun. 2021;12(1):511.","journal-title":"Nat Commun"},{"issue":"8","key":"4993_CR115","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1016\/j.ymthe.2017.04.024","volume":"25","author":"E Drent","year":"2017","unstructured":"Drent E, Themeli M, Poels R, de Jong-Korlaar R, Yuan H, de Bruijn J, et al. A rational strategy for reducing on-target off-tumor effects of CD38-chimeric antigen receptors by affinity optimization. Mol Ther. 2017;25(8):1946\u201358.","journal-title":"Mol Ther"},{"issue":"2","key":"4993_CR116","first-page":"86","volume":"70","author":"LB Kennedy","year":"2020","unstructured":"Kennedy LB, Salama AKS. A review of cancer immunotherapy toxicity. CA Cancer J Clin. 2020;70(2):86\u2013104.","journal-title":"CA Cancer J Clin"},{"issue":"11","key":"4993_CR117","first-page":"e49452","volume":"15","author":"R Patel","year":"2023","unstructured":"Patel R, Patel M, Laxmidhar F, Lakhatariya K, Patel D, Patel Z, et al. Cytokine release syndrome in patients treated with chimeric antigen receptor T-cell therapy: a retrospective study analyzing risks, outcomes, and healthcare burden. Cureus. 2023;15(11):e49452.","journal-title":"Cureus"},{"issue":"4","key":"4993_CR118","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1038\/nrclinonc.2018.19","volume":"15","author":"DT Teachey","year":"2018","unstructured":"Teachey DT, Bishop MR, Maloney DG, Grupp SA. Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit \u201cALL.\u201d Nat Rev Clin Oncol. 2018;15(4):218.","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"4993_CR119","first-page":"50","volume":"66","author":"J Gauthier","year":"2018","unstructured":"Gauthier J, Turtle CJ. Insights into cytokine release syndrome and neurotoxicity after CD19-specific CAR-T cell therapy. Curr Res Transl Med. 2018;66(2):50\u20132.","journal-title":"Curr Res Transl Med"},{"issue":"6","key":"4993_CR120","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/s41591-018-0041-7","volume":"24","author":"T Giavridis","year":"2018","unstructured":"Giavridis T, van der Stegen SJC, Eyquem J, Hamieh M, Piersigilli A, Sadelain M. CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade. Nat Med. 2018;24(6):731\u20138.","journal-title":"Nat Med"},{"key":"4993_CR121","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.blre.2018.11.002","volume":"34","author":"JN Brudno","year":"2019","unstructured":"Brudno JN, Kochenderfer JN. Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management. Blood Rev. 2019;34:45\u201355.","journal-title":"Blood Rev"},{"key":"4993_CR122","doi-asserted-by":"publisher","first-page":"611366","DOI":"10.3389\/fimmu.2021.611366","volume":"12","author":"Z Yan","year":"2021","unstructured":"Yan Z, Zhang H, Cao J, Zhang C, Liu H, Huang H, et al. Characteristics and risk factors of cytokine release syndrome in chimeric antigen receptor T cell treatment. Front Immunol. 2021;12:611366.","journal-title":"Front Immunol"},{"key":"4993_CR123","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1200\/EDBK_238691","volume":"39","author":"B Santomasso","year":"2019","unstructured":"Santomasso B, Bachier C, Westin J, Rezvani K, Shpall EJ. The other side of CAR T-cell therapy: cytokine release syndrome, neurologic toxicity, and financial burden. Am Soc Clin Oncol Educ Book. 2019;39:433\u201344.","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"8","key":"4993_CR124","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1080\/1744666X.2019.1629904","volume":"15","author":"C Kotch","year":"2019","unstructured":"Kotch C, Barrett D, Teachey DT. Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome. Expert Rev Clin Immunol. 2019;15(8):813\u201322.","journal-title":"Expert Rev Clin Immunol"},{"issue":"3","key":"4993_CR125","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1080\/17474086.2019.1585238","volume":"12","author":"UH Acharya","year":"2019","unstructured":"Acharya UH, Dhawale T, Yun S, Jacobson CA, Chavez JC, Ramos JD, et al. Management of cytokine release syndrome and neurotoxicity in chimeric antigen receptor (CAR) T cell therapy. Expert Rev Hematol. 2019;12(3):195\u2013205.","journal-title":"Expert Rev Hematol"},{"issue":"5","key":"4993_CR126","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1080\/15563650.2021.1880008","volume":"59","author":"DN Lipe","year":"2021","unstructured":"Lipe DN, Shafer S. CAR-T and checkpoint inhibitors: toxicities and antidotes in the emergency department. Clin Toxicol (Phila). 2021;59(5):376\u201385.","journal-title":"Clin Toxicol (Phila)"},{"key":"4993_CR127","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.actbio.2023.10.002","volume":"172","author":"N Mohaghegh","year":"2023","unstructured":"Mohaghegh N, Ahari A, Zehtabi F, Buttles C, Davani S, Hoang H, et al. Injectable hydrogels for personalized cancer immunotherapies. Acta Biomater. 2023;172:67\u201391.","journal-title":"Acta Biomater"},{"issue":"11","key":"4993_CR128","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1016\/j.drudis.2016.07.006","volume":"21","author":"M Norouzi","year":"2016","unstructured":"Norouzi M, Nazari B, Miller DW. Injectable hydrogel-based drug delivery systems for local cancer therapy. Drug Discov Today. 2016;21(11):1835\u201349.","journal-title":"Drug Discov Today"},{"issue":"2","key":"4993_CR129","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1039\/D3NH00401E","volume":"9","author":"G Xu","year":"2024","unstructured":"Xu G, Liu K, Chen X, Lin Y, Yu C, Nie X, et al. Hydrogel-mediated tumor T cell infiltration and immune evasion to reinforce cancer immunotherapy. Nanoscale Horiz. 2024;9(2):295\u2013304.","journal-title":"Nanoscale Horiz"},{"issue":"9","key":"4993_CR130","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1038\/s41551-021-00712-1","volume":"5","author":"Q Hu","year":"2021","unstructured":"Hu Q, Li H, Archibong E, Chen Q, Ruan H, Ahn S, et al. Inhibition of post-surgery tumour recurrence via a hydrogel releasing CAR-T cells and anti-PDL1-conjugated platelets. Nat Biomed Eng. 2021;5(9):1038\u201347.","journal-title":"Nat Biomed Eng"},{"key":"4993_CR131","doi-asserted-by":"crossref","unstructured":"Rushdi M, Li K, Yuan Z, Travaglino S, Grakoui A, Zhu C. Mechanotransduction in T Cell Development, Differentiation and Function. Cells. 2020;9(2).","DOI":"10.3390\/cells9020364"},{"issue":"2","key":"4993_CR132","doi-asserted-by":"publisher","first-page":"e70009","DOI":"10.1111\/sji.70009","volume":"101","author":"X Wu","year":"2025","unstructured":"Wu X, Ye Z. Mechanoimmunology of T-cell activation. Scand J Immunol. 2025;101(2):e70009.","journal-title":"Scand J Immunol"},{"issue":"21","key":"4993_CR133","doi-asserted-by":"publisher","first-page":"e2300670","DOI":"10.1002\/advs.202300670","volume":"10","author":"Y Shou","year":"2023","unstructured":"Shou Y, Teo XY, Wu KZ, Bai B, Kumar ARK, Low J, et al. Dynamic stimulations with bioengineered extracellular matrix-mimicking hydrogels for mechano cell reprogramming and therapy. Adv Sci. 2023;10(21):e2300670.","journal-title":"Adv Sci"},{"issue":"5","key":"4993_CR134","doi-asserted-by":"publisher","first-page":"e2304569","DOI":"10.1002\/adhm.202304569","volume":"14","author":"R Janssen","year":"2025","unstructured":"Janssen R, Benito-Zarza L, Cleijpool P, Valverde MG, Mih\u0103il\u0103 SM, Bastiaan-Net S, et al. Biofabrication directions in recapitulating the immune system-on-a-chip. Adv Healthc Mater. 2025;14(5):e2304569.","journal-title":"Adv Healthc Mater"},{"key":"4993_CR135","doi-asserted-by":"crossref","unstructured":"Moran-Alvarez A, Gonzalez-Menendez P, Mayo JC, Sainz RM. Reflections on the biology of cell culture models: living on the edge of oxidative metabolism in cancer cells. Int J Mol Sci. 2023;24(3).","DOI":"10.3390\/ijms24032717"},{"key":"4993_CR136","doi-asserted-by":"crossref","unstructured":"Nguyen DT, Ogando-Rivas E, Liu R, Wang T, Rubin J, Jin L, et al. CAR T Cell locomotion in solid tumor microenvironment. Cells. 2022;11(12).","DOI":"10.3390\/cells11121974"},{"key":"4993_CR137","doi-asserted-by":"crossref","unstructured":"Wu Y, Xiao Y, Yin B, Wong SHD. Dynamic Hydrogels: adaptive biomaterials for engineering tumor microenvironment and cancer treatment. Int J Mol Sci. 2025;26(19).","DOI":"10.3390\/ijms26199502"},{"issue":"39","key":"4993_CR138","doi-asserted-by":"publisher","first-page":"e06429","DOI":"10.1002\/smll.202506429","volume":"21","author":"G Marsico","year":"2025","unstructured":"Marsico G, Gc S, Siciliano V. Synthetic biology and biomaterials strategies to deceive the tumor microenvironment in CAR-T immunotherapy. Small. 2025;21(39):e06429.","journal-title":"Small"},{"issue":"37","key":"4993_CR139","doi-asserted-by":"publisher","first-page":"e2503384","DOI":"10.1002\/smll.202503384","volume":"21","author":"X Sun","year":"2025","unstructured":"Sun X, Zhang Z, Zhao W, Xu S, Zhang J, Zhuansun X, et al. Prediction of CAR-T therapy in vitro: development of biomimetic models for CAR-T killing effect assessment. Small. 2025;21(37):e2503384.","journal-title":"Small"},{"issue":"1","key":"4993_CR140","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1186\/s12967-024-05102-0","volume":"22","author":"Q Liu","year":"2024","unstructured":"Liu Q, Xu R, Shen J, Tao Y, Shao J, Ke Y, et al. In situ chemoimmunotherapy hydrogel elicits immunogenic cell death and evokes efficient antitumor immune response. J Transl Med. 2024;22(1):341.","journal-title":"J Transl Med"},{"key":"4993_CR141","doi-asserted-by":"publisher","first-page":"113761","DOI":"10.1016\/j.jconrel.2025.113761","volume":"383","author":"SM Mantooth","year":"2025","unstructured":"Mantooth SM, Green JM, Green WD, Nguyen KG, Mantooth KA, Meritet DM, et al. An injectable hydrogel enhances intratumoral retention and antitumor efficacy of cytokine immunotherapy in murine triple negative breast tumor models. J Control Release. 2025;383:113761.","journal-title":"J Control Release"},{"key":"4993_CR142","doi-asserted-by":"crossref","unstructured":"Kim J, Choi Y, Kim DH, Yoon HY, Kim K. Injectable hydrogel-based combination cancer immunotherapy for overcoming localized therapeutic efficacy. Pharmaceutics. 2022;14(9).","DOI":"10.3390\/pharmaceutics14091908"},{"key":"4993_CR143","doi-asserted-by":"publisher","first-page":"671611","DOI":"10.3389\/fphar.2021.671611","volume":"12","author":"H Zhang","year":"2021","unstructured":"Zhang H, Zhang J, Liu Y, Jiang Y, Li Z. Molecular targeted agent and immune checkpoint inhibitor co-loaded thermosensitive hydrogel for synergistic therapy of rectal cancer. Front Pharmacol. 2021;12:671611.","journal-title":"Front Pharmacol"},{"issue":"23","key":"4993_CR144","doi-asserted-by":"publisher","first-page":"e2201271","DOI":"10.1002\/advs.202201271","volume":"9","author":"Y Gong","year":"2022","unstructured":"Gong Y, Chen W, Chen X, He Y, Jiang H, Zhang X, et al. An injectable epigenetic autophagic modulatory hydrogel for boosting umbilical cord blood NK cell therapy prevents postsurgical relapse of triple-negative breast cancer. Adv Sci. 2022;9(23):e2201271.","journal-title":"Adv Sci"},{"issue":"33","key":"4993_CR145","doi-asserted-by":"publisher","first-page":"37514","DOI":"10.1021\/acsami.2c10727","volume":"14","author":"J Jie","year":"2022","unstructured":"Jie J, Mao D, Cao J, Feng P, Yang P. Customized multifunctional peptide hydrogel scaffolds for CAR-T-cell rapid proliferation and solid tumor immunotherapy. ACS Appl Mater Interfaces. 2022;14(33):37514\u201327.","journal-title":"ACS Appl Mater Interfaces"},{"key":"4993_CR146","doi-asserted-by":"publisher","first-page":"925985","DOI":"10.3389\/fimmu.2022.925985","volume":"13","author":"MP Jogalekar","year":"2022","unstructured":"Jogalekar MP, Rajendran RL, Khan F, Dmello C, Gangadaran P, Ahn BC. CAR T-cell-based gene therapy for cancers: new perspectives, challenges, and clinical developments. Front Immunol. 2022;13:925985.","journal-title":"Front Immunol"},{"key":"4993_CR147","doi-asserted-by":"publisher","first-page":"105266","DOI":"10.1016\/j.ebiom.2024.105266","volume":"106","author":"TA Bui","year":"2024","unstructured":"Bui TA, Mei H, Sang R, Ortega DG, Deng W. Advancements and challenges in developing in vivo CAR T cell therapies for cancer treatment. EBioMedicine. 2024;106:105266.","journal-title":"EBioMedicine"},{"issue":"7","key":"4993_CR148","doi-asserted-by":"publisher","first-page":"3226","DOI":"10.1039\/D3NR05768B","volume":"16","author":"Y Lin","year":"2024","unstructured":"Lin Y, Chen Y, Luo Z, Wu YL. Recent advances in biomaterial designs for assisting CAR-T cell therapy towards potential solid tumor treatment. Nanoscale. 2024;16(7):3226\u201342.","journal-title":"Nanoscale"},{"key":"4993_CR149","doi-asserted-by":"publisher","first-page":"115331","DOI":"10.1016\/j.addr.2024.115331","volume":"210","author":"SC Adams","year":"2024","unstructured":"Adams SC, Nambiar AK, Bressler EM, Raut CP, Colson YL, Wong WW, et al. Immunotherapies for locally aggressive cancers. Adv Drug Deliv Rev. 2024;210:115331.","journal-title":"Adv Drug Deliv Rev"},{"issue":"4","key":"4993_CR150","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s11427-016-5026-5","volume":"59","author":"W Wang","year":"2016","unstructured":"Wang W, Qin DY, Zhang BL, Wei W, Wang YS, Wei YQ. Establishing guidelines for CAR-T cells: challenges and considerations. Sci China Life Sci. 2016;59(4):333\u20139.","journal-title":"Sci China Life Sci"},{"issue":"6","key":"4993_CR151","doi-asserted-by":"publisher","first-page":"404","DOI":"10.4049\/immunohorizons.2400008","volume":"8","author":"S Underwood","year":"2024","unstructured":"Underwood S, Jin J, Shao L, Prochazkova M, Shi R, Song HW, et al. T cell activators exhibit distinct downstream effects on chimeric antigen receptor T cell phenotype and function. Immunohorizons. 2024;8(6):404\u201314.","journal-title":"Immunohorizons"},{"issue":"19","key":"4993_CR152","doi-asserted-by":"publisher","first-page":"7424","DOI":"10.7150\/thno.101941","volume":"14","author":"R Lv","year":"2024","unstructured":"Lv R, Guo Y, Liu W, Dong G, Liu X, Li C, et al. Revolutionizing cancer treatment: the emerging potential and potential challenges of in vivo self-processed CAR cell therapy. Theranostics. 2024;14(19):7424\u201347.","journal-title":"Theranostics"},{"issue":"1","key":"4993_CR153","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s10565-025-10064-0","volume":"41","author":"H Chang","year":"2025","unstructured":"Chang H, Wei H, Qi Y, Ding S, Li H, Si S. Advances in hybrid hydrogel design for biomedical applications: innovations in drug delivery and tissue engineering for gynecological cancers. Cell Biol Toxicol. 2025;41(1):115.","journal-title":"Cell Biol Toxicol"},{"issue":"19","key":"4993_CR154","doi-asserted-by":"publisher","first-page":"e2310637","DOI":"10.1002\/adma.202310637","volume":"36","author":"A Skirzynska","year":"2024","unstructured":"Skirzynska A, Xue C, Shoichet MS. Engineering biomaterials to model immune-tumor interactions in vitro. Adv Mater. 2024;36(19):e2310637.","journal-title":"Adv Mater"},{"key":"4993_CR155","doi-asserted-by":"publisher","first-page":"122052","DOI":"10.1016\/j.biomaterials.2023.122052","volume":"295","author":"Y Chao","year":"2023","unstructured":"Chao Y, Wei T, Li Q, Liu B, Hao Y, Chen M, et al. Metformin-containing hydrogel scaffold to augment CAR-T therapy against post-surgical solid tumors. Biomaterials. 2023;295:122052.","journal-title":"Biomaterials"},{"issue":"5","key":"4993_CR156","doi-asserted-by":"publisher","first-page":"e2310078","DOI":"10.1002\/adma.202310078","volume":"36","author":"C Zhu","year":"2024","unstructured":"Zhu C, Ke L, Ao X, Chen Y, Cheng H, Xin H, et al. Injectable supramolecular hydrogels for in situ programming of car-T cells toward solid tumor immunotherapy. Adv Mater. 2024;36(5):e2310078.","journal-title":"Adv Mater"},{"issue":"1","key":"4993_CR157","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s40164-024-00542-2","volume":"13","author":"X Gu","year":"2024","unstructured":"Gu X, Zhang Y, Zhou W, Wang F, Yan F, Gao H, et al. Infusion and delivery strategies to maximize the efficacy of CAR-T cell immunotherapy for cancers. Exp Hematol Oncol. 2024;13(1):70.","journal-title":"Exp Hematol Oncol"},{"issue":"11","key":"4993_CR158","doi-asserted-by":"publisher","first-page":"16548","DOI":"10.1021\/acsami.4c19942","volume":"17","author":"M Castellote-Borrell","year":"2025","unstructured":"Castellote-Borrell M, Domingo M, Merlina F, Lu H, Colell S, Bachiller M, et al. Lymph-node inspired hydrogels enhance CAR expression and proliferation of CAR T cells. ACS Appl Mater Interfaces. 2025;17(11):16548\u201360.","journal-title":"ACS Appl Mater Interfaces"},{"issue":"14","key":"4993_CR159","doi-asserted-by":"publisher","first-page":"eabn8264","DOI":"10.1126\/sciadv.abn8264","volume":"8","author":"AK Grosskopf","year":"2022","unstructured":"Grosskopf AK, Labanieh L, Klysz DD, Roth GA, Xu P, Adebowale O, et al. Delivery of CAR-T cells in a transient injectable stimulatory hydrogel niche improves treatment of solid tumors. Sci Adv. 2022;8(14):eabn8264.","journal-title":"Sci Adv"},{"issue":"15","key":"4993_CR160","doi-asserted-by":"publisher","first-page":"4044","DOI":"10.1039\/D5BM00656B","volume":"13","author":"C Zhang","year":"2025","unstructured":"Zhang C, Li H, Li Z, Hao K, Tian H. Naturally-derived injectable hydrogels for antitumor therapeutics. Biomater Sci. 2025a;13(15):4044\u201361.","journal-title":"Biomater Sci"},{"key":"4993_CR161","doi-asserted-by":"publisher","first-page":"101477","DOI":"10.1016\/j.tranon.2022.101477","volume":"24","author":"AB Suraiya","year":"2022","unstructured":"Suraiya AB, Evtimov VJ, Truong VX, Boyd RL, Forsythe JS, Boyd NR. Micro-hydrogel injectables that deliver effective CAR-T immunotherapy against 3D solid tumor spheroids. Transl Oncol. 2022;24:101477.","journal-title":"Transl Oncol"},{"issue":"14","key":"4993_CR162","doi-asserted-by":"publisher","first-page":"3887","DOI":"10.1039\/D5BM00612K","volume":"13","author":"N Kim","year":"2025","unstructured":"Kim N, Kim J, Choi J, Kim R. A collagen hydrogel-based intestinal model enabling physiological epithelial-immune cell interactions in host-microbe studies. Biomater Sci. 2025;13(14):3887\u2013902.","journal-title":"Biomater Sci"},{"issue":"5","key":"4993_CR163","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1039\/D3BM01840G","volume":"12","author":"Y Cheng","year":"2024","unstructured":"Cheng Y, Zhang H, Wei H, Yu CY. Injectable hydrogels as emerging drug-delivery platforms for tumor therapy. Biomater Sci. 2024;12(5):1151\u201370.","journal-title":"Biomater Sci"},{"key":"4993_CR164","doi-asserted-by":"publisher","first-page":"113985","DOI":"10.1016\/j.jconrel.2025.113985","volume":"385","author":"H Yu","year":"2025","unstructured":"Yu H, Zhang J, Yang L, Tian Y, Milne C, Jin P, et al. MSC-derived exosomes injectable hyaluronic acid hydrogel for enhanced chronic wound healing. J Control Release. 2025;385:113985.","journal-title":"J Control Release"},{"key":"4993_CR165","doi-asserted-by":"publisher","first-page":"122128","DOI":"10.1016\/j.carbpol.2024.122128","volume":"336","author":"P Wang","year":"2024","unstructured":"Wang P, Li R, Ma J, Zhang W, Shen H, Ren Y, et al. Facilitating safe and sustained submucosal lift through an endoscopically injectable shear-thinning carboxymethyl starch sodium hydrogel. Carbohydr Polym. 2024b;336:122128.","journal-title":"Carbohydr Polym"},{"key":"4993_CR166","doi-asserted-by":"publisher","first-page":"102421","DOI":"10.1016\/j.mtbio.2025.102421","volume":"35","author":"YC Zeng","year":"2025","unstructured":"Zeng YC, Sun YQ, Zhang XQ, Liang SJ, Chen LL, Zhang KY, et al. Injectable tert-butylphenylacetic acid\/acrylated \u03b2-cyclodextrin-based hydrogels for co-delivery of CAR-T cells and IL-15 in solid tumor therapy. Mater Today Bio. 2025;35:102421.","journal-title":"Mater Today Bio"},{"key":"4993_CR167","doi-asserted-by":"crossref","unstructured":"Fatoni A, Wijonarko A, Anggraeni MD, Hermawan D, Diastuti H, Zusfahair. Alginate NiFe(2)O(4) nanoparticles cryogel for electrochemical glucose biosensor development. Gels. 2021;7(4).","DOI":"10.3390\/gels7040272"},{"key":"4993_CR168","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.actbio.2025.02.026","volume":"195","author":"Q Huang","year":"2025","unstructured":"Huang Q, Qu Y, Tang M, Lan K, Zhang Y, Chen S, et al. ROS-responsive hydrogel for bone regeneration: controlled dimethyl fumarate release to reduce inflammation and enhance osteogenesis. Acta Biomater. 2025;195:183\u2013200.","journal-title":"Acta Biomater"},{"key":"4993_CR169","first-page":"100174","volume":"5","author":"SF Elhabal","year":"2023","unstructured":"Elhabal SF, Ghaffar SA, Hager R, Elzohairy NA, Khalifa MM, Mohie PM, et al. Development of thermosensitive hydrogel of Amphotericin-B and Lactoferrin combination-loaded PLGA-PEG-PEI nanoparticles for potential eradication of ocular fungal infections: In-vitro, ex-vivo and in-vivo studies. Int J Pharm X. 2023;5:100174.","journal-title":"Int J Pharm X"},{"key":"4993_CR170","doi-asserted-by":"crossref","unstructured":"Xue Y, Fan L, Liu H, Chen H, Bian K, Bai H, et al. Photo-crosslinkable hydrogel with programmable dual time-phase drug release for accelerated healing of infected diabetic wounds. J Adv Res. 2025.","DOI":"10.1016\/j.jare.2025.11.015"},{"issue":"5","key":"4993_CR171","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","volume":"24","author":"M Binnewies","year":"2018","unstructured":"Binnewies M, Roberts EW, Kersten K, Chan V, Fearon DF, Merad M, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 2018;24(5):541\u201350.","journal-title":"Nat Med"},{"issue":"6","key":"4993_CR172","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/s41577-019-0127-6","volume":"19","author":"DG DeNardo","year":"2019","unstructured":"DeNardo DG, Ruffell B. Macrophages as regulators of tumour immunity and immunotherapy. Nat Rev Immunol. 2019;19(6):369\u201382.","journal-title":"Nat Rev Immunol"},{"issue":"8","key":"4993_CR173","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/nri3862","volume":"15","author":"EJ Wherry","year":"2015","unstructured":"Wherry EJ, Kurachi M. Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol. 2015;15(8):486\u201399.","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"4993_CR174","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.it.2015.02.008","volume":"36","author":"KE Pauken","year":"2015","unstructured":"Pauken KE, Wherry EJ. Overcoming T cell exhaustion in infection and cancer. Trends Immunol. 2015;36(4):265\u201376.","journal-title":"Trends Immunol"},{"issue":"3","key":"4993_CR175","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1016\/j.fmre.2023.05.016","volume":"5","author":"Y Liu","year":"2025","unstructured":"Liu Y, Hao Y, Lv X, Zhang Y, Chen J, Tian J, et al. A tetramethylpyrazine releasing hydrogel can potentiate CAR-T cell therapy against triple negative breast cancer by reprogramming tumor vasculatures. Fundam Res. 2025;5(3):1288\u201397.","journal-title":"Fundam Res"},{"key":"4993_CR176","doi-asserted-by":"publisher","DOI":"10.3390\/nano11020471","author":"J Kim","year":"2021","unstructured":"Kim J, Francis DM, Thomas SN. In situ crosslinked hydrogel depot for sustained antibody release improves immune checkpoint blockade cancer immunotherapy. Nanomaterials. 2021. https:\/\/doi.org\/10.3390\/nano11020471.","journal-title":"Nanomaterials"},{"key":"4993_CR177","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.canlet.2022.01.006","volume":"529","author":"L Shen","year":"2022","unstructured":"Shen L, Xiao Y, Tian J, Lu Z. Remodeling metabolic fitness: strategies for improving the efficacy of chimeric antigen receptor T cell therapy. Cancer Lett. 2022;529:139\u201352.","journal-title":"Cancer Lett"},{"issue":"8010","key":"4993_CR178","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/s41586-024-07242-1","volume":"629","author":"JD Chan","year":"2024","unstructured":"Chan JD, Scheffler CM, Munoz I, Sek K, Lee JN, Huang YK, et al. FOXO1 enhances CAR T cell stemness, metabolic fitness and efficacy. Nature. 2024;629(8010):201\u201310.","journal-title":"Nature"},{"issue":"1","key":"4993_CR179","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/nbt.3104","volume":"33","author":"SB Stephan","year":"2015","unstructured":"Stephan SB, Taber AM, Jileaeva I, Pegues EP, Sentman CL, Stephan MT. Biopolymer implants enhance the efficacy of adoptive T-cell therapy. Nat Biotechnol. 2015;33(1):97\u2013101.","journal-title":"Nat Biotechnol"},{"issue":"8","key":"4993_CR180","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1038\/nbt.4181","volume":"36","author":"L Tang","year":"2018","unstructured":"Tang L, Zheng Y, Melo MB, Mabardi L, Casta\u00f1o AP, Xie YQ, et al. Enhancing T cell therapy through TCR-signaling-responsive nanoparticle drug delivery. Nat Biotechnol. 2018;36(8):707\u201316.","journal-title":"Nat Biotechnol"},{"issue":"1","key":"4993_CR181","doi-asserted-by":"publisher","first-page":"91","DOI":"10.7150\/thno.34851","volume":"10","author":"G Nagel","year":"2020","unstructured":"Nagel G, Sousa-Herves A, Wedepohl S, Calder\u00f3n M. Matrix metalloproteinase-sensitive multistage nanogels promote drug transport in 3D tumor model. Theranostics. 2020;10(1):91\u2013108.","journal-title":"Theranostics"},{"key":"4993_CR182","doi-asserted-by":"publisher","first-page":"1523436","DOI":"10.3389\/fimmu.2025.1523436","volume":"16","author":"B Zhang","year":"2025","unstructured":"Zhang B, Li M, Ji J, Si X, Yin X, Ji G, et al. A syringeable immunotherapeutic hydrogel enhances T cell immunity via in-situ activation of STING pathway for advanced breast cancer postoperative therapy. Front Immunol. 2025b;16:1523436.","journal-title":"Front Immunol"},{"issue":"27","key":"4993_CR183","doi-asserted-by":"publisher","first-page":"5629","DOI":"10.1039\/C5TB00443H","volume":"3","author":"E Secret","year":"2015","unstructured":"Secret E, Crannell KE, Kelly SJ, Villancio-Wolter M, Andrew JS. Matrix metalloproteinase-sensitive hydrogel microparticles for pulmonary drug delivery of small molecule drugs or proteins. J Mater Chem B. 2015;3(27):5629\u201334.","journal-title":"J Mater Chem B"},{"issue":"5","key":"4993_CR184","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1158\/2326-6066.CIR-18-0466","volume":"7","author":"D Alizadeh","year":"2019","unstructured":"Alizadeh D, Wong RA, Yang X, Wang D, Pecoraro JR, Kuo CF, et al. IL15 enhances CAR-T cell antitumor activity by reducing mTORC1 activity and preserving their stem cell memory phenotype. Cancer Immunol Res. 2019;7(5):759\u201372.","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"4993_CR185","doi-asserted-by":"publisher","first-page":"e37823","DOI":"10.1002\/jbm.a.37823","volume":"113","author":"GD Lizana-Vasquez","year":"2025","unstructured":"Lizana-Vasquez GD, Ramasubramanian S, Davarzani A, Cappabianca D, Saha K, Karumbaiah L, et al. In vitro assessment of thermo-responsive scaffold as a 3D synthetic matrix for CAR-T potency testing against glioblastoma spheroids. J Biomed Mater Res A. 2025;113(1):e37823.","journal-title":"J Biomed Mater Res A"},{"key":"4993_CR186","doi-asserted-by":"publisher","first-page":"1596499","DOI":"10.3389\/fimmu.2025.1596499","volume":"16","author":"S Yaacoub","year":"2025","unstructured":"Yaacoub S, Vannoy E, Maslova S, Haffey A, Khorsandi K, Sheybani N, et al. CAR-T cell therapy in brain malignancies: obstacles in the face of cellular trafficking and persistence. Front Immunol. 2025;16:1596499.","journal-title":"Front Immunol"},{"issue":"14","key":"4993_CR187","doi-asserted-by":"publisher","first-page":"7090","DOI":"10.7150\/thno.114257","volume":"15","author":"M Ijaz","year":"2025","unstructured":"Ijaz M, Tan Q, Yan Y, Zhang D, Chen Q, Zhang Y, et al. Overcoming barriers in glioblastoma: the potential of CAR T cell immunotherapy. Theranostics. 2025;15(14):7090\u2013126.","journal-title":"Theranostics"},{"issue":"36","key":"4993_CR188","doi-asserted-by":"publisher","first-page":"46988","DOI":"10.1021\/acsami.4c02317","volume":"16","author":"S Sun","year":"2024","unstructured":"Sun S, Chen J. Recent advances in hydrogel-based biosensors for cancer detection. ACS Appl Mater Interfaces. 2024;16(36):46988\u20137002.","journal-title":"ACS Appl Mater Interfaces"},{"key":"4993_CR189","doi-asserted-by":"publisher","DOI":"10.3390\/bioengineering12030254","author":"P Sutar","year":"2025","unstructured":"Sutar P, Pethe A, Kumar P, Tripathi D, Maity D. Hydrogel innovations in biosensing: a new frontier for pancreatitis diagnostics. Bioengineering. 2025. https:\/\/doi.org\/10.3390\/bioengineering12030254.","journal-title":"Bioengineering"},{"key":"4993_CR190","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.jconrel.2022.06.008","volume":"348","author":"F Zisi Tegou","year":"2022","unstructured":"Zisi Tegou F, Velluto D, Stock AA, Fitzgerald SN, Stealey S, Zustiak SP, et al. CCL21 and beta-cell antigen releasing hydrogels as tolerance-inducing therapy in Type I diabetes. J Control Release. 2022;348:499\u2013517.","journal-title":"J Control Release"},{"issue":"9","key":"4993_CR191","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1038\/nm.2198","volume":"16","author":"MT Stephan","year":"2010","unstructured":"Stephan MT, Moon JJ, Um SH, Bershteyn A, Irvine DJ. Therapeutic cell engineering with surface-conjugated synthetic nanoparticles. Nat Med. 2010;16(9):1035\u201341.","journal-title":"Nat Med"},{"key":"4993_CR192","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.coi.2015.01.002","volume":"33","author":"MC Jensen","year":"2015","unstructured":"Jensen MC, Riddell SR. Designing chimeric antigen receptors to effectively and safely target tumors. Curr Opin Immunol. 2015;33:9\u201315.","journal-title":"Curr Opin Immunol"},{"issue":"14","key":"4993_CR193","doi-asserted-by":"publisher","first-page":"e2306889","DOI":"10.1002\/advs.202306889","volume":"11","author":"Y Ke","year":"2024","unstructured":"Ke Y, Xin K, Tao Y, Li L, Chen A, Shao J, et al. A thermosensitive bi-adjuvant hydrogel triggers epitope spreading to promote the anti-tumor efficacy of frameshift neoantigens. Adv Sci (Weinh). 2024;11(14):e2306889.","journal-title":"Adv Sci (Weinh)"},{"issue":"1","key":"4993_CR194","doi-asserted-by":"publisher","first-page":"8364","DOI":"10.1038\/s41467-024-52753-0","volume":"15","author":"W Song","year":"2024","unstructured":"Song W, Lee C, Jeong H, Kim S, Hwang NS. Sprayable anti-adhesive hydrogel for peritoneal macrophage scavenging in post-surgical applications. Nat Commun. 2024;15(1):8364.","journal-title":"Nat Commun"},{"key":"4993_CR195","doi-asserted-by":"publisher","first-page":"120041","DOI":"10.1016\/j.ijpharm.2020.120041","volume":"592","author":"P Roy","year":"2021","unstructured":"Roy P, Mignet N, Pocard M, Boudy V. Drug delivery systems to prevent peritoneal metastasis after surgery of digestives or ovarian carcinoma: a review. Int J Pharm. 2021;592:120041.","journal-title":"Int J Pharm"},{"key":"4993_CR196","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics12100921","author":"A Nicolas","year":"2020","unstructured":"Nicolas A, Dejoux A, Poirier C, Aubrey N, P\u00e9an JM, Velge-Roussel F. Contribution of intrinsic fluorescence to the design of a new 3D-printed implant for releasing SDABS. Pharmaceutics. 2020. https:\/\/doi.org\/10.3390\/pharmaceutics12100921.","journal-title":"Pharmaceutics"},{"key":"4993_CR197","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15102426","author":"B Yathavan","year":"2023","unstructured":"Yathavan B, Chhibber T, Steinhauff D, Pulsipher A, Alt JA, Ghandehari H, et al. Matrix-mediated delivery of silver nanoparticles for prevention of Staphylococcus aureus and Pseudomonas aeruginosa biofilm formation in chronic rhinosinusitis. Pharmaceutics. 2023. https:\/\/doi.org\/10.3390\/pharmaceutics15102426.","journal-title":"Pharmaceutics"},{"issue":"8","key":"4993_CR198","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1080\/02713683.2017.1287277","volume":"42","author":"S Kinoshita","year":"2017","unstructured":"Kinoshita S, Ohguchi T, Noda K, Murata M, Yasueda SI, Obata H, et al. Evaluation of the safety and tolerability of conjunctival ring for posterior segment of the eye. Curr Eye Res. 2017;42(8):1149\u201354.","journal-title":"Curr Eye Res"},{"issue":"9","key":"4993_CR199","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1016\/j.ymthe.2017.06.008","volume":"25","author":"AJ Walker","year":"2017","unstructured":"Walker AJ, Majzner RG, Zhang L, Wanhainen K, Long AH, Nguyen SM, et al. Tumor antigen and receptor densities regulate efficacy of a chimeric antigen receptor targeting anaplastic lymphoma kinase. Mol Ther. 2017;25(9):2189\u2013201.","journal-title":"Mol Ther"},{"key":"4993_CR200","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25105361","author":"KS Ku","year":"2024","unstructured":"Ku KS, Tang J, Chen Y, Shi Y. Current advancements in anti-cancer chimeric antigen receptor T cell immunotherapy and how nanotechnology may change the game. Int J Mol Sci. 2024. https:\/\/doi.org\/10.3390\/ijms25105361.","journal-title":"Int J Mol Sci"},{"key":"4993_CR201","doi-asserted-by":"publisher","first-page":"1590534","DOI":"10.3389\/fonc.2025.1590534","volume":"15","author":"L Zhu","year":"2025","unstructured":"Zhu L, Qiao G, Gao H, Jiang A, Zhang L, Wang X. Enhancing melanoma therapy with hydrogel microneedles. Front Oncol. 2025;15:1590534.","journal-title":"Front Oncol"},{"issue":"10","key":"4993_CR202","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1038\/s43018-020-00127-y","volume":"1","author":"A Nellan","year":"2020","unstructured":"Nellan A, Fry TJ. Optimizing CARs for ocular delivery. Nat Cancer. 2020;1(10):939\u201340.","journal-title":"Nat Cancer"},{"issue":"3","key":"4993_CR203","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/s41571-019-0297-y","volume":"17","author":"S Rafiq","year":"2020","unstructured":"Rafiq S, Hackett CS, Brentjens RJ. Engineering strategies to overcome the current roadblocks in CAR T cell therapy. Nat Rev Clin Oncol. 2020;17(3):147\u201367.","journal-title":"Nat Rev Clin Oncol"},{"key":"4993_CR204","doi-asserted-by":"publisher","DOI":"10.3390\/gels10070440","author":"R Solanki","year":"2024","unstructured":"Solanki R, Bhatia D. Stimulus-responsive hydrogels for targeted cancer therapy. Gels. 2024. https:\/\/doi.org\/10.3390\/gels10070440.","journal-title":"Gels"},{"key":"4993_CR205","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13051164","author":"F Andrade","year":"2021","unstructured":"Andrade F, Roca-Melendres MM, Dur\u00e1n-Lara EF, Rafael D, Schwartz S Jr. Stimuli-responsive hydrogels for cancer treatment: the role of pH, light, ionic strength and magnetic field. Cancers (Basel). 2021. https:\/\/doi.org\/10.3390\/cancers13051164.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"4993_CR206","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1158\/0008-5472.CAN-06-1017","volume":"67","author":"U Thanarajasingam","year":"2007","unstructured":"Thanarajasingam U, Sanz L, Diaz R, Qiao J, Sanchez-Perez L, Kottke T, et al. Delivery of CCL21 to metastatic disease improves the efficacy of adoptive T-cell therapy. Cancer Res. 2007;67(1):300\u20138.","journal-title":"Cancer Res"},{"key":"4993_CR207","doi-asserted-by":"publisher","DOI":"10.3390\/polym16202943","author":"EO Bakhrushina","year":"2024","unstructured":"Bakhrushina EO, Afonina AM, Mikhel IB, Demina NB, Plakhotnaya ON, Belyatskaya AV, et al. Role of sterilization on in situ gel-forming polymer stability. Polymers. 2024. https:\/\/doi.org\/10.3390\/polym16202943.","journal-title":"Polymers"},{"issue":"1","key":"4993_CR208","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/s41392-024-01852-x","volume":"9","author":"P Lu","year":"2024","unstructured":"Lu P, Ruan D, Huang M, Tian M, Zhu K, Gan Z, et al. Harnessing the potential of hydrogels for advanced therapeutic applications: current achievements and future directions. Signal Transduct Target Ther. 2024;9(1):166.","journal-title":"Signal Transduct Target Ther"},{"key":"4993_CR209","doi-asserted-by":"publisher","first-page":"821094","DOI":"10.3389\/fmed.2022.821094","volume":"9","author":"ME Reis","year":"2022","unstructured":"Reis ME, Bettencourt A, Ribeiro HM. The regulatory challenges of innovative customized combination products. Front Med (Lausanne). 2022;9:821094.","journal-title":"Front Med (Lausanne)"},{"issue":"40","key":"4993_CR210","doi-asserted-by":"publisher","first-page":"17332","DOI":"10.1002\/anie.202002780","volume":"59","author":"S Yan","year":"2020","unstructured":"Yan S, Luo Z, Li Z, Wang Y, Tao J, Gong C, et al. Improving cancer immunotherapy outcomes using biomaterials. Angew Chem Int Ed Engl. 2020;59(40):17332\u201343.","journal-title":"Angew Chem Int Ed Engl"},{"key":"4993_CR211","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.3389\/fimmu.2018.01717","volume":"9","author":"R Elahi","year":"2018","unstructured":"Elahi R, Khosh E, Tahmasebi S, Esmaeilzadeh A. Immune cell hacking: challenges and clinical approaches to create smarter generations of chimeric antigen receptor T cells. Front Immunol. 2018;9:1717.","journal-title":"Front Immunol"},{"issue":"3","key":"4993_CR212","doi-asserted-by":"publisher","first-page":"nwab172","DOI":"10.1093\/nsr\/nwab172","volume":"9","author":"H Li","year":"2022","unstructured":"Li H, Wang Z, Ogunnaike EA, Wu Q, Chen G, Hu Q, et al. Scattered seeding of CAR T cells in solid tumors augments anticancer efficacy. Natl Sci Rev. 2022;9(3):nwab172.","journal-title":"Natl Sci Rev"}],"container-title":["Stem Cell Research & Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13287-026-04993-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-026-04993-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-026-04993-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T07:06:11Z","timestamp":1778655971000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13287-026-04993-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,2]]},"references-count":212,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4993"],"URL":"https:\/\/doi.org\/10.1186\/s13287-026-04993-8","relation":{},"ISSN":["1757-6512"],"issn-type":[{"value":"1757-6512","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,2]]},"assertion":[{"value":"20 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"181"}}